| INTRODUCTION
Oral mesalazine is the most commonly prescribed treatment for patients with mild-to-moderate active ulcerative colitis (UC). [1] [2] [3] Once-daily mesalazine dosing is as effective and safe as dosing schedules that feature multi-tablet regimens administered two to four times daily. 4, 5 The primary advantage of less frequent dosing schedules is the potential for greater medication adherence and effectiveness. Community-based research indicates that adherence and persistence rates for mesalazine are as low as 40%-60% 6,7 and 13%-45% 8, 9 respectively. Evidence that poor adherence translates into reduced effectiveness has been generated by a cohort study that followed 4453 UC patients for a median of 6 years. This study demonstrated that low adherence was the most powerful predictor of disease flare. 10 Strategies to improve medication adherence might result in better outcomes in UC. Thus, establishing simplified dosing regimens based upon once-daily administration of a minimum number of tablets is a priority.
A once-daily 1600 mg tablet-based mesalazine preparation with novel starch-based coating technology (OPTICORE: Tillotts Pharma AG, Rheinfelden, Switzerland) (Tillotts' OPTICORE has been developed based on the Phloral technology) that utilises both traditional pH-triggered and enzymatic-triggered release was developed to improve dosing convenience and ensure consistent drug release within the colon.
We compared this once-daily 1600 mg tablet-based mesalazine to a twice-daily 400 mg tablet-based regimen (both Tillotts Pharma AG, Rheinfelden, Switzerland) for induction of remission in UC.
| MATERIAL AND METHODS
This phase III, randomised, active-controlled, double-dummy, multicentre, non-inferiority induction trial with an open-label extension was conducted between July 15, 2013 and May 17, 2016 in patients with mild-to-moderate active UC at 179 centres in Europe and Canada. Ethics committees at each study site approved the protocol and all patients provided written informed consent.
The study was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonization Good Clinical Practice Guidelines, and is registered at Clinicaltrials.gov (NCT01903252).
| Study population
Patients ≥18 years with a documented diagnosis of UC were eligible provided they had mild-to-moderate active UC extending ≥15 cm from the anal verge, a total Mayo Clinic Score (MCS) 11 ≥5, a rectal bleeding subscore ≥1, and a Mayo Clinic Endoscopic Subscale (MCES) score ≥2 determined by central reading. Key exclusion criteria included diagnosis of severe UC, defined as the presence of ≥6 bloody stools daily with one or more of the following: (1) oral temperature >37.8°C
or >100.0°F; (2) pulse >90 beats/min; (3) haemoglobin concentration <10 g/dL. Patients treated with oral mesalazine >2.5 g/d; systemic steroids or rectal steroids within 4 weeks prior to randomisation; rectal mesalazine (within 2 weeks); immunosuppressants (within 6 weeks); infliximab or any other biologics (within 12 weeks); antibiotics, anti-diarrhoeals or nicotine patch (within 1 week); or administration of any investigational drug (within 4 weeks) were also excluded.
Patients receiving mesalazine ≤2.5 g/d had to discontinue therapy at randomisation. Additional exclusion criteria were a history of colectomy or partial colectomy; a history of colorectal dysplasia; Crohn's disease; toxic megacolon; bleeding disorders; hypersensitivity to salicylates, aspirin, sulfasalazine or 5-aminosalicylic acid; serum creatinine >1.5 times the upper limit of normal; aspartate aminotransferase, alanine aminotransferase, total bilirubin or alkaline phosphatase >2 times the upper limit of normal; serious underlying disease other than UC;
history of drug or alcohol abuse or a stool culture positive for Clostridium difficile. Pregnant or lactating women were also excluded.
| Design
Eligible patients were randomised (1:1) to receive 3.2 g of oral mesalazine, administered as two 1600 mg tablets each morning or four 400 mg tablets twice-daily, for 8 weeks (see Figure 1 for tablet dimensions). To preserve blinding all patients took the same number of identical appearing 1600 mg or 400 mg placebo tablets. The randomisation schedule was generated by computer in permuted blocks of 6 without stratification. An interactive web response system was used to manage randomisation and dispense the study drug. Investigators, central readers, and patients were unaware of treatment assignment.
Patients with clinical and endoscopic response (decrease from baseline in the MCS >3 points and ≥30%, with a ≥1-point decrease in the rectal bleeding subscore or an absolute rectal bleeding subscore of 0 or 1) or remission (MCS ≤2 with no individual subscore >1) at week 8 continued blinded treatment until week 12.
Following the non-inferiority induction study, patients were eligi- Figure 2 ).
| Efficacy and safety evaluations
Patients were assessed at the screening visit (weekÀ1) and weeks 0, 
| Primary outcomes
The primary efficacy outcome in the randomised study was the proportion of patients in clinical and endoscopic remission at week 8.
16
In the open-label extension, the primary efficacy outcome was the proportion of patients in clinical remission at week 38.
| Secondary outcomes
In the randomised study, the main secondary outcomes in hierar- 
| Statistical methods
Since the trial was designed to show non-inferiority, the primary and secondary outcomes were analysed on the basis of the perprotocol (PP) population, although the primary endpoint was also assessed with the intention-to-treat (ITT) population. The ITT population included any patient who received a dose of the study drug whereas the PP population excluded ITT patients with any pre-defined, major protocol deviation that could have affected the primary endpoint. Major protocol deviations were reviewed by a blinded adjudication committee who decided by consensus whether a patient should be included in the ITT or PP population.
While ITT is a conservative approach to analyses of superiority trials, PP analyses are more sensitive to treatment effect in noninferiority trials. 21 Outcomes in the open-label extension were analysed using the ITT population.
For primary efficacy outcomes and all other dichotomous secondary outcomes, between-group differences and the two-sided 95% confidence interval (CI) for the estimated difference were calculated using Newcombe's method, with the P-value for non-inferiority obtained by conversion of confidence limits. 22 For continuous outcomes, means and 95% CIs were calculated.
Differences in changes from baseline between treatment groups were compared using a two-sample t test.
To control for multiple comparisons, 10 main secondary endpoints were ranked and tested in a hierarchical order. 23 Formal statistical testing stopped with the first endpoint that failed the noninferiority criterion.
An analysis that adjusted for important covariates at baseline (age, sex, geographical region, disease extent, disease severity, treatment history, histological severity, faecal urgency) was also performed for clinical and endoscopic remission, endoscopic remission, clinical remission and rectal bleeding subscores of 0 at week 8.
Patients who withdrew prior to weeks 8, 16 or 38, or for whom response status was not evaluable due to incomplete and/or invalid data, were considered nonremitters or nonresponders.
Sample size was based on historical data and assumed a 40% remission rate in both groups. 24 Based upon a non-inferiority margin of 10%, 377 evaluable PP patients per group were required to provide 80% power at the two-sided 0.05 level of significance. Assuming no more than 6% of patients would be excluded from the PP analysis, a sample size of 800 patients was considered sufficient to demonstrate non-inferiority.
Univariable associations between PRO2-defined remission failure 20 at week 8 and independent baseline predictors were assessed post hoc using logistic regression analysis. The performance of the model was quantified using the c-statistic and the Hosmer-Lemesbow test. 25 The predictive value of histopathology and endoscopy was of particular interest. PR02 was selected as the dependent variable as it is a clinically based measure that does not incorporate histopathology or endoscopy. (Table S1 ).
In total, 737 patients completed the randomised study (90.5% and 90.0% in the 1600 mg and 400 mg groups, respectively) and 727 ( Figure 4 ). When these results were adjusted for baseline characteristics, the between-group difference was À1.2% (95% CI: À7.3% to 5.0%) ( Figure 5 ). The ITT analysis for clinical and endoscopic remission at week 8 was concordant with the PP analysis, and found the 1600 mg tablet to be non-inferior to the 400 mg tablet, with a between-group difference of À1.8% (95% CI: À7.5% to 4.0%). Similarly, a post-hoc analysis in patients with histologically confirmed disease (Geboes score ≥3.1) revealed a between-group difference of À1.1% (95% CI: À7.3% to 5.1%), and À0.2% (95% CI: À6.6% to 6.2%) when adjusted for baseline characteristics. Non-responder at week 16: 1 (0, 0, 1) Other: 4 (1, 2, 1)
Of the 1141 patients screened for eligibility, 324 were excluded, 409 were randomised to the 1600 mg tablet group and 408 were randomised to the 400 mg tablet group. At week 8, 370 patients in the 1600 mg group and 367 patients in the 400 mg group were evaluable. Of these patients, 243 did not respond to treatment and entered the 4. Table S3 .
| Safety
In the randomised induction study, at least one adverse event was Tables S4 and S5 .
Clinically, significant nephrotoxicity (a serum creatinine increase >26.5 lmol/L or 1.5-2.0-fold increase in serum creatinine from baseline) is estimated to affect up to one in 500 ulcerative colitis patients receiving mesalazine. It should be noted that none of the patients had a >1.5-fold increase in serum creatinine from baseline over the course of the study. F I G U R E 4 Primary and secondary outcomes in the randomised study. The primary outcome in the randomised, noninferiority trial was met with a baseline difference of À2.2% (95% confidence interval: À8.1% to 3.8%, P=.005). The main secondary outcomes were ranked and tested in hierarchical order. The criterion for non-inferiority was met for the first outcome, however, since the lower bound of the between-group difference for the second outcome exceeded the noninferiority margin of 10%, formal statistical testing was ceased at this point 
Baseline-adjusted primary and secondary outcomes in the randomised study. An analysis that adjusted for pre-specified covariates at baseline including age, sex, geographical region, disease extent, disease severity, treatment history, histologic severity and faecal urgency was performed. The noninferiority criterion was met for the primary outcome and the first two secondary outcomes. Formal statistical testing was ceased with the third secondary outcome since the lower bound of the between-group difference exceeded the non-inferiority margin of 10%
| Regression analysis
Higher endoscopic and histopathologic disease activity, higher leucocyte concentration and younger age were associated with PR02-defined treatment failure at week 8 (Table 1) .
| DISCUSSION
In the largest trial of mesalazine induction therapy performed to date evaluating the highest concentration mesalazine preparation yet formulated, mesalazine 1600 mg administered as two tablets once-daily was non-inferior to mesalazine 400 mg administered as four tablets twice-daily. Although the 2.2% point estimate of the between-group treatment difference in the PP analysis appeared to favour the 400 mg tablet based regimen, the lower bound of the 95% confidence interval for this estimate (À8.1% to 3.8%) was within the prespecified margin to conclude non-inferiority (P=.005). Furthermore, when this difference was adjusted for relevant baseline characteristics the between-group difference was further reduced to 1.2% (95% CI: À7.3% to 5.0%). The most important baseline factors accounting for the reduced difference following adjustment were MCS, faecal urgency and treatment history. The results of the ITT analysis were consistent with the PP analysis, with an estimated between-group difference of À1.8% (95% CI: À7.5% to 4.0%). Thus, results from both analytical perspectives indicate that the high concentration oral mesalazine formulation (1600 mg) is non-inferior to a conventional formulation (400 mg). Furthermore, a post-hoc analysis in patients with histologically confirmed disease supported these findings (between-group difference À1.1%, 95% CI: À7.3% to 5.1%).
These results are noteworthy given that histologic disease activity is increasingly recognised as an important parameter in clinical trials and a prognostic marker in clinical practice. 26 Given that there were 10 secondary endpoints, a ranked hierar- With regard to safety, the incidence of serious and drug-related adverse events was low and did not differ between treatment groups, consistent with the well-established and favourable safety profile of mesalazine. 4, 5 When data from the current, large study is included in a previously published meta-analysis on oral 5-ASA for induction of remission in ulcerative colitis, the pooled relative risk estimate for the outcome "failure to induce clinical remission" changes from 0.94 (95% CI: 0.83-1.07) 4 to 0.99, and the confidence interval tightens (95% CI: 0.92-1.06), thereby increasing the precision of the point estimate ( Figure S1 ).
The remission rates observed in this study deserve comment because of their implications for future trial planning. At the time of protocol development, a remission rate of 40% was a conservative estimate based on the 3.2 g/d mesalazine regimen using 400 mg tablets. 24 However, remission rates in this study were considerably lower in both treatment groups. It is noteworthy that this is the first trial of high concentration mesalazine to employ central reading, and that blinded endoscopic video assessment systematically generates lower remission rates compared to local reads. 12 A recently published meta-analysis found that enroling patients with more severe disease (MCES>2) in UC trials was associated with lower placebo rates. 13 Also, patients in this study likely had more severe disease at entry compared with historical trials. For example, the proportion of patients in this trial with a baseline MCS ≥6 was 94.8% (774/817), whereas 63.1% and 60.8% of patients had baseline Modified Ulcerative Colitis Disease Activity Scores between 6 and 10 in studies that used local endoscopy scores for enrolment. 24, 27 The most compelling reason for developing a high concentration mesalazine formulation is to reduce tablet burden and dosing frequency, and improve adherence. Due to the double-dummy trial design, pill burden was equal in the two groups, precluding assessment of any potential benefit of the high concentration tablet on adherence. Furthermore, since all patients received the same number of "large" (1600 mg or placebo) and "small" (400 mg or placebo) tablets, for a total of 10 tablets daily, the impact of the relatively larger size of the 1600 mg tablet on patient tolerability and adherence could not be assessed.
Numerous observational studies have documented low rates of adherence in patients receiving multi-tablet mesalazine maintenance therapy. 6, 7, 28 However, no trial comparing high and low concentration mesalazine formulations has demonstrated increased adherence with the high concentration preparations. 24, 27, [29] [30] [31] [32] [33] [34] [35] [36] [37] This is likely explained by the clinical trial environment where adherence is monitored and the need to take assigned medication is reinforced, and the often used double-dummy design. Evaluation of mesalazine pill burden and tablet size on adherence rates and clinical outcomes requires well-designed experiments conducted in the "real world" community gastroenterology practice. Cluster randomisation designs have been used for this purpose in other settings. [38] [39] [40] The multivariate model showed that higher endoscopic and histopathologic disease activity, higher leucocyte concentration and younger age were associated with failure to achieve remission at week 8. These preliminary data are encouraging as resolution of objective measures of disease activity are increasingly recognised as important for long-term outcomes. However, this model was not sufficiently robust to be used in clinical practice for identifying high-risk patients. Research to identify factors that predict mesalazine treatment outcomes is needed.
In summary, induction therapy with 3.2 g/d mesalazine administered once-daily using a novel, 1600 mg tablet with a dual-delivery coating was statistically and clinically non-inferior to a twice-daily regimen using a 400 mg tablet. Extended treatment with the 1600 mg tablet at a reduced dose of one tablet/d was effective for maintenance of remission and well-tolerated. 
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